Our work has also indicated that in the cohort of HCC patients with SPTBN1 low/IL-1β high, or SPTBN1 low/IL-6 high, the loss of SPTBN1 and increased level of IL-1β or IL-6 correlates with shorter relapse-free survival, which highlights SPTBN1, IL-1β, and IL-6 as prognostic biomarkers for clinical outcome in HCC patients. Here, IL6 is linked to hepatocellular carcinoma.